anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cantharidin
Trial phase: Phase 2
SMILES: [H][C@]12CC[C@]([H])(O1)[C@]1(C)C(=O)OC(=O)[C@@]12C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 30
Group description: Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.

Cantharidin: Application of topical cantharidin
Eligibility criteria:
Inclusion Criteria:

Diagnosis of MC by the Principal Investigator.

Maximum of 50 lesions on locations including the face, trunk, back, left or right arm, left or right leg, hands, feet, buttocks, and groin.

Execution of Informed Consent and or assent forms

Exclusion Criteria:

Patients with immunosuppression, including organ transplantation, HIV infection.

Patients utilizing immunosuppressive agents (including oral corticosteroids) will be excluded except for patients using inhaled corticosteroids, such as those utilized for asthma or allergic rhinitis.

Females who have reached menarche and are sexually active as well as pregnant patients will be excluded as the effects of this drug have not been evaluated in pregnancy.

Patients who have greater than 50 MC lesions will also be excluded from the study.
Intervention: Premarin
Trial phase: Phase 4
ATC code: G03CA57
SMILES: CC12CCC3c4ccc(OS(=O)(=O)[O-])cc4CCC3C1CCC2=O.[Na+]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Women randomized to this arm received 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Interested in resuming or continuing sexual activity
Greater than 12 months since last menstrual cycle or prior bilateral oophorectomy
Dyspareunia as a vulvovaginal atrophy symptom
Normal mammogram within 12 months prior to entry into the study

Exclusion Criteria:

History or suspicion of breast carcinoma
History of hormone-dependent tumor
Genital bleeding of unknown cause
Ongoing vaginal infection
History of cerebrovascular accident (CVA), myocardial infarction (MI) or heart disease
Uncontrolled hypertension (HTN) over 160/100
Serious disease or chronic condition that may prevent completion of study
Body Mass Index (BMI) over 40
Hypercoagulable state, or currently on anticoagulant therapy
Use of any exogenous sex hormone within three months from study entry, or during the study
Pelvic surgery within the last 12 months
Intervention: Difamilast
Trial phase: Phase 2
SMILES: CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 24
Group description: Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.

OPA-15406
Eligibility criteria:
Inclusion Criteria:

Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

Exclusion Criteria:

Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a sudden intensification of atopic dermatitis.
Subjects who have an active viral skin infection.
Subjects with a current or history of malignancy.
Intervention: Difamilast
Trial phase: Phase 2
SMILES: CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 25
Group description: Subjects were treated with assigned 1% OPA-15406 ointment twice daily.

OPA-15406
Eligibility criteria:
Inclusion Criteria:

Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

Exclusion Criteria:

Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a sudden intensification of atopic dermatitis.
Subjects who have an active viral skin infection.
Subjects with a current or history of malignancy.
Intervention: Tacrolimus
Trial phase: Phase 4
ATC code: D11AH01 | L04AD02
SMILES: C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.

Tacrolimus: See description in arm/group sections
Eligibility criteria:
Inclusion Criteria:

All new kidney transplant recipients aged 18 to 65 years who are admitted at UNC-CH and provided informed consent will be included in this study.

Exclusion Criteria:

- Patients will be excluded from participating in the study to receive genotype-guided tacrolimus dosing if he/she meets any of the exclusion criteria described below.

Recipients who did not consent to participate in the study.
Highly sensitized patients (ie, pretransplant T or B cell flow crossmatch positive)
Recipients of ABO incompatible kidney transplant
Recipients with preformed donor-specific antibodies (DSA)
Human Leukocyte Antigen (HLA) identical kidney transplant
Recipients of non-kidney transplant
Recipients of repeat transplant if they are on immunosuppression at the time of transplant
Patients using medications that have known pharmacokinetic (PK) drug interaction with tacrolimus
Patients in whom tacrolimus therapy is contraindicated
Intervention: Hydroxyurea
Trial phase: Phase 2
ATC code: L01XX05
SMILES: NC(=O)NO
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 26
Group description: In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
Eligibility criteria:
Inclusion Criteria:

Children with HbSS or sickle hemoglobin (HbS)/β^0thalassemia
≥9 to ≤ 36 months of age at study initiation
Enrollment will occur irrespective of clinical severity

Exclusion Criteria:

Permanent:

Receiving chronic red blood cell transfusion therapy.
Condition or chronic illness, which in the opinion of the PI makes participation unsafe.

Transient (participants may be re-evaluated after ≥14 days):

Recent (<30 days) participation in another clinical intervention trial utilizing an investigational new drug/investigational device exemption (IND/IDE) agent.
Erythrocyte transfusion in the past 2 months.

Laboratory Assessments:

Hemoglobin <6.0 g/dL
Absolute reticulocyte count <80 * 10^3/µL if hemoglobin <9.0 mg/dL
Absolute neutrophil count <1.5 * 10^3/µL
Platelet count <100 * 10^3/µL
Serum creatinine > twice the upper limit of normal for age
Alanine aminotransferase (ALT) > twice the upper limit of normal
Intervention: Hydroxyurea
Trial phase: Phase 2
ATC code: L01XX05
SMILES: NC(=O)NO
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 25
Group description: In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
Eligibility criteria:
Inclusion Criteria:

Children with HbSS or sickle hemoglobin (HbS)/β^0thalassemia
≥9 to ≤ 36 months of age at study initiation
Enrollment will occur irrespective of clinical severity

Exclusion Criteria:

Permanent:

Receiving chronic red blood cell transfusion therapy.
Condition or chronic illness, which in the opinion of the PI makes participation unsafe.

Transient (participants may be re-evaluated after ≥14 days):

Recent (<30 days) participation in another clinical intervention trial utilizing an investigational new drug/investigational device exemption (IND/IDE) agent.
Erythrocyte transfusion in the past 2 months.

Laboratory Assessments:

Hemoglobin <6.0 g/dL
Absolute reticulocyte count <80 * 10^3/µL if hemoglobin <9.0 mg/dL
Absolute neutrophil count <1.5 * 10^3/µL
Platelet count <100 * 10^3/µL
Serum creatinine > twice the upper limit of normal for age
Alanine aminotransferase (ALT) > twice the upper limit of normal
Intervention: Glutathione
Trial phase: Phase 2
ATC code: V03AB32
SMILES: N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 30
Group description: Oral Glutathione oral powder at 65mg/kg/day

Oral Glutathione: Oral Glutathione oral powder
Eligibility criteria:
Inclusion Criteria:

Male or female ≥ 2 and < 11 years of age at Visit 1
Documentation of a CF diagnosis as evidenced by the following criteria: Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) AND Two well-characterized mutations in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
Weight-for-age between the 10th and 50th percentiles at Screening (Visit 1) (using the Center for Disease Control (CDC) reference equations)
Current chronic use, greater than 8 weeks before Day 0, of pancreatic enzyme replacement therapy (PERT) for management of pancreatic insufficiency
Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability to comply with the requirements of the study
Clinically stable with no significant changes in health status within 2 weeks prior to Day 0

Exclusion Criteria:

1. Intestinal obstruction or gastrointestinal surgery within the 6 months prior to Day 0 2. History of diabetes, Crohn's disease, celiac disease, or bowel resection 3. Use of either oral or inhaled GSH or N-acetyl cysteine within the 4 months prior to Screening (Visit 1) 4. Known hypersensitivity to oral glutathione or lactose 5. Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, Pulmozyme, Cayston TOBI Kalydeco,Orkambi, Proton Pump Inhibitor, Histamine H-2 Blocker [PPI/H2-blocker], Miralax® , PERT, dietary supplementation, probiotics) within the 4 weeks prior to Day 0 6. Changes in the amount of proprietary dietary supplement formulas (e.g., Scandishakes, Boost, Pediasure, or homemade formula) given (oral or gastrostomy tube) within the 4 weeks prior to Day 0 7. Use of antibiotics (oral, IV, or inhaled) for acute symptoms within the 2 weeks prior to Day 0 8. Use of oral steroids within the 4 weeks prior to Day 0 9. Active treatment for nontuberculous mycobacteria (NTM) at Day 0 10. Active treatment for allergic bronchopulmonary aspergillosis (ABPA) at Day 0 11. Administration of any investigational drug within the 30 days prior to Day 0 12. Sibling who received study drug as part of this study 13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Intervention: Mefloquine
Trial phase: Phase 4
ATC code: P01BC02 | P01BF02
SMILES: OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 89
Group description: Participants received a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc Q2W (starting at Week 6 until Week 94).
Eligibility criteria:
Inclusion Criteria:

Subjects must have a documented diagnosis of adult-onset axial Spondyloarthritis (axSpA) with at least 3 months' symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria
Subjects must have active disease at Screening as defined by
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4
Spinal pain >= 4 on a 0 to 10 Numerical Rating Scale (NRS; from BASDAI item 2)
Nonradiographic (Nr)-axSpA subjects must either have C-reactive protein (CRP) > upper limit of normal (ULN) and /or current evidence of sacroiliitis on magnetic resonance imaging (MRI) (no confirmation by central reading) as defined by ASAS criteria
Ankylosing spondylitis (AS) subjects must have evidence of sacroiliitis on x-ray meeting the modified New York (mNY) classification criteria according to the Investigator
Subjects must have a documented history of Anterior Uveitis (AU) diagnosed by an ophthalmologist and have at least 2 AU flares in the past, of which at least 1 AU flare was in the last 12 months prior to Baseline

Exclusion Criteria:

Other inflammatory arthritis
Secondary, noninflammatory condition that, in the Investigator's opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of axial spondyloarthritis (axSpA)
Any history of uveitis except for Anterior Uveitis (AU) associated with axSpA
Any condition or complicating factor that may interfere with the AU assessment
Retisert® or Iluvien® (glucocorticosteroid implant) within 3 years prior to the Baseline Visit or has had complications related to the device
Subject has had Retisert or Iluvien (glucocorticosteroid implant) removed within 90 days prior to the Baseline Visit
Intraocular or periocular corticosteroids within 90 days prior to the Baseline visit
Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline Visit
Cyclophosphamide within 30 days prior to the Baseline Visit
Intravitreal methotrexate (MTX) within 90 days prior to the Baseline Visit
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy
Intervention: Colchicine
Trial phase: Phase 3
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 179
Group description: Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.

Colchicine: colchicine given as per trial protocol
Eligibility criteria:
Inclusion Criteria:

All consecutive adult patients undergoing elective cardiac surgery

Exclusion Criteria:

Documented history of AF or supraventricular arrhythmia or, absence of sinus rhythm on hospital admission
Known severe liver disease or current transaminases >1.5 times the upper normal limit
Current serum creatinine >2.5 mg/dl
Known myopathy or elevated baseline preoperative creatine kinase
Known blood dyscrasias
Significant gastrointestinal disease
Pregnant and lactating women
Known hypersensitivity to colchicine
Current treatment with colchicine for any indications
Emergency surgery
Intervention: Velpatasvir
Trial phase: Phase 2
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 102
Group description: PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) fixed-dose combination (FDC) 400/100 mg tablets once daily for 7 days. Participants who completed the PK lead-in phase, continued into the treatment phase with no interruption of study drug administration and additional participants were enrolled into the treatment phase once the appropriateness of the dose was confirmed by PK results from the PK lead-in phase.

Treatment Phase: SOF/VEL 400/100 mg (adult and smaller size tablets based on swallowability assessment) once daily for 12 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Chronic HCV-infected, treatment-naive and treatment-experienced adolescent and pediatric individuals aged 3 to < 18 as determined at Day 1.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Velpatasvir
Trial phase: Phase 2
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 73
Group description: PK Lead-in Phase: SOF/VEL FDC 200/50 mg tablets or oral granules once daily for 7 days. Participants who completed the PK lead-in phase, continued into the treatment phase with no interruption of study drug administration and additional participants were enrolled into the treatment phase once the appropriateness of the dose was confirmed by PK results from the PK lead-in phase.

Treatment Phase: SOF/VEL FDC 200/50 mg tablets or oral granules once daily for 12 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Chronic HCV-infected, treatment-naive and treatment-experienced adolescent and pediatric individuals aged 3 to < 18 as determined at Day 1.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Velpatasvir
Trial phase: Phase 2
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 41
Group description: PK Lead-in Phase: SOF/VEL FDC 200/50 mg oral granules once daily for 7 days for participants who weighed ≥ 17 kg. SOF/VEL FDC 150/37.5 mg oral granules once daily for 7 days for participants who weighed < 17 kg. Participants who completed the PK lead-in phase, continued into the treatment phase with no interruption of study drug administration and additional participants were enrolled into the treatment phase once the appropriateness of the dose was confirmed by PK results from the PK lead-in phase.

Treatment Phase: SOF/VEL FDC 200/50 mg oral granules once daily for 12 weeks for participants who weighed ≥ 17 kg. SOF/VEL FDC 150/37.5 mg oral granules once daily for 12 weeks for participants who weighed < 17 kg.
Eligibility criteria:
Key Inclusion Criteria:

Chronic HCV-infected, treatment-naive and treatment-experienced adolescent and pediatric individuals aged 3 to < 18 as determined at Day 1.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: ASCORBIC ACID
Trial phase: Phase 4
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Acthar administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly for 6 months of treatment with a cumulative dose exposure of 3,920 units.
Eligibility criteria:
Inclusion Criteria:

Age 18 to 70 years
Free of immunosuppression for at least 3 months
Capability of understanding the purpose of the study
Written informed consent

Exclusion Criteria:

Epidermal growth factor receptor (eGFR) < 30ml/min/1.73m2
Kidney Transplant
Secondary MN (defined on the basis of clinical criteria)
Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational diabetes mellitus is not an exclusion)
History of previous use of Acthar for treatment of nephrotic syndrome
Prior sensitivity to Acthar or other porcine protein products
Contraindication to Acthar per Prescribing Information
Planned treatment with live or live attenuated vaccines once enrolled in the study
More than three previous treatment regiments
Participation to other clinical trials over the previous 12 months
History of cancer, except carcinoma in situ and treated basal and squamous cell carcinomas
Pregnancy
Lactation
Current substance abuse
Any clinically relevant condition that might affect study participation and/or study results
Intervention: Nepafenac
Trial phase: Not Applicable
ATC code: S01BC10
SMILES: NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 331
Group description: nepafenac 0.3% ophthalmic solution dosed once daily

Nepafenac 0.3%
Eligibility criteria:
Inclusion Criteria:

Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.

Exclusion Criteria:

previous uveitis (<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 331
Group description: sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily

Saline Solution
Eligibility criteria:
Inclusion Criteria:

Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.

Exclusion Criteria:

previous uveitis (<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 41
Group description: Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock

0.9% Sodium Chloride: Inject 10 mL of 0.9% NaCl into cervical stroma
Eligibility criteria:
Inclusion Criteria:

Undergoing laparoscopic hysterectomy with or without salpingoophorectomy for benign indications
Undergoing laparoscopic hysterectomy with robotic assistance with or without salpingoophorectomy for benign indications
Between 18 and 60 years of age

Exclusion Criteria:

Intraoperative detection of malignancy
Undergoing additional procedures at the time of surgery (except prophylactic McCall culdoplasty/uterosacral ligament suspension, excision of endometriosis, appendectomy, cystoscopy)
Inability to perform paracervical block due to anatomic abnormalities (absent/flush cervix)
Known allergy/sensitivity to bupivacaine
Intraoperative bowel injury, bladder injury, ureter injury or major vessel injury that required repair.
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 41
Group description: Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.

Bupivacaine: Inject 10 mL of 0.5% bupivacaine into cervical stroma
Eligibility criteria:
Inclusion Criteria:

Undergoing laparoscopic hysterectomy with or without salpingoophorectomy for benign indications
Undergoing laparoscopic hysterectomy with robotic assistance with or without salpingoophorectomy for benign indications
Between 18 and 60 years of age

Exclusion Criteria:

Intraoperative detection of malignancy
Undergoing additional procedures at the time of surgery (except prophylactic McCall culdoplasty/uterosacral ligament suspension, excision of endometriosis, appendectomy, cystoscopy)
Inability to perform paracervical block due to anatomic abnormalities (absent/flush cervix)
Known allergy/sensitivity to bupivacaine
Intraoperative bowel injury, bladder injury, ureter injury or major vessel injury that required repair.
Intervention: Ketorolac
Trial phase: Phase 4
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants may be randomized to receive Ketorolac for their TPI.

Ketorolac: Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Eligibility criteria:
Inclusion Criteria:

Men or women age 18 or over
At least one active trigger point

Exclusion Criteria:

Allergy or contraindication to any NSAID, CS, or local anesthetic
Receiving anticoagulant medication
History of bleeding disorder
Pregnant or breast feeding women
Gastrointestinal ulceration
Pre-existing renal disease
Pre-existing congestive heart failure
Diabetes mellitus
Prior myocardial infarction or stroke
Fibromyalgia